Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center

References

• Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012; 8: 413–425.
   PubMed Web of Science ®Google Scholar
• Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010; 138: 1383–1394.
   PubMed Web of Science ®Google Scholar
• Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. Rheumatology (Oxford).2012; 51:1846–54
   Google Scholar
• Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009; 60: 569–577.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology. 2009; 48: 304–308.
   PubMed Web of Science ®Google Scholar
• Condliffe R. Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179: 151–157.
   PubMed Web of Science ®Google Scholar
• Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol. 2011; 40: 127–132.
   PubMed Web of Science ®Google Scholar
• Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest. 2011; 140: 301–309.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334: 296–302.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132: 425–434.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sanchez O, Fartoukh M, Jagot JL, Gall C, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999; 13: 1351–1356.
   PubMed Web of Science ®Google Scholar
• Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000; 117: 14–18.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477–1482.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40: 780–788.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54: S78–S84.
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arboqast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Resipr Crit Care Med. 2003; 167: 580–586.
   PubMed Web of Science ®Google Scholar
• Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009; 36: 2244–2249.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–590.
   Google Scholar
• Kasukawa R, Tojo T, Miyawaki S. Kasukawa R, Sharp GC. Preliminary diagnostic criteria for classification of MCTD. Mixed connective tissue disease and anti-nuclear antibodies. 1987ElsevierAmsterdam23–32.
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61: 554–558.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 30: S55–S66.
   Google Scholar
• Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994; 37: 75–83.
   PubMed Web of Science ®Google Scholar
• Klings E, Hill N, Ieong M, Simms R, Korn J, Farber H. Systemic sclerosis-associated pulmonary hypertension. Arthritis Rheum. 1999; 42: 2638–2645.
   PubMed Web of Science ®Google Scholar
• Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010; 74: 2200–2205.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respir Med.. 2012; 106: 730–739.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F, Schemuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895–900.
   PubMed Web of Science ®Google Scholar
• Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000; 118: 1077–1082.
   PubMedGoogle Scholar